<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773678</url>
  </required_header>
  <id_info>
    <org_study_id>CBP-201-WW002</org_study_id>
    <nct_id>NCT04773678</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Connect Biopharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Connect Biopharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with&#xD;
      moderate to severe persistent asthma with Type 2 inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, parallel group, placebo-controlled study to&#xD;
      assess the efficacy and safety of two dose levels of CBP-201 administered to eligible&#xD;
      patients with moderate to severe persistent asthma with Type 2 inflammation compared to&#xD;
      placebo. CBP-201 is administered as a subcutaneous (SC) injection. The study is divided into&#xD;
      a treatment period of 24 weeks and a follow-up period of 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in prebronchodilator (trough) forced expiratory volume in the first second of expiration (FEV1)</measure>
    <time_frame>at Week 12</time_frame>
    <description>Absolute change from Baseline in prebronchodilator (trough) FEV1 at Week 12. To assess the efficacy of CBP-201 (Dose 1 and Dose 2) versus placebo in patients with moderate to severe persistent asthma with type 2 inflammation as measured by lung function improvements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in prebronchodilator (trough) FEV1</measure>
    <time_frame>at Weeks 1, 2, 4, 8 and 24</time_frame>
    <description>Absolute change from Baseline in prebronchodilator (trough) FEV1 at Weeks 1, 2, 4, 8 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in prebronchodilator (trough) FEV1</measure>
    <time_frame>at Weeks 1, 2, 4, 8, 12 and 24</time_frame>
    <description>Percent change from Baseline in prebronchodilator (trough) FEV1 at Weeks 1, 2, 4, 8, 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in other lung function measurements</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Change from Baseline in other lung function measurements [percentage predicted FEV1, morning and evening peak expiratory flow (PEF)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to severe exacerbation and number of events</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Time to severe exacerbation and number of events during the 24 weeks Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥ 1 asthma exacerbation</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Proportion of patients with ≥ 1 asthma exacerbation during the 24 weeks Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, type and severity of Adverse Event (AE)</measure>
    <time_frame>From Baseline to Week 32</time_frame>
    <description>Safety endpoints will be summarized by descriptive statistics and narratives where indicated by severity. Safety will be assessed on basis of AEs reported, including SAEs and AESIs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Steady-state trough PK profile)</measure>
    <time_frame>From Baseline to Week 32</time_frame>
    <description>Whole blood for plasma CBP-201 concentrations will be obtained and analyzed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Moderate to Severe Persistent Asthma</condition>
  <arm_group>
    <arm_group_label>CBP-201 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 Dose 1 subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBP-201 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 Dose 2 subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous (SC) injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBP-201</intervention_name>
    <description>CBP-201 subcutaneous (SC) injection.</description>
    <arm_group_label>CBP-201 Dose 1</arm_group_label>
    <arm_group_label>CBP-201 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous (SC) injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult male or female patient aged 18 to 75 years with a physician diagnosis of asthma&#xD;
             for a minimum of 12 months, based on the Global Initiative for Asthma (GINA) 2020&#xD;
             Guidelines.&#xD;
&#xD;
          2. Patient is currently receiving treatment with medium to high dose inhaled&#xD;
             corticosteroids (ICS) in combination with at least 1 additional reliever/controller&#xD;
             for at least 90 days prior to the Screening Visit with a stable dose of ICS at least&#xD;
             28 days prior to the Screening Visit.&#xD;
&#xD;
             Note:&#xD;
&#xD;
               -  Patients receiving ICS equivalent to ≥ 250 μg fluticasone propionate twice daily&#xD;
                  or equipotent ICS daily dosage of a maximum of 2000 μg/day fluticasone propionate&#xD;
                  (or equivalent) in combination with a second reliever/controller (eg, long-acting&#xD;
                  ß agonist [LABA], leukotriene receptor antagonist [LTRA], long-acting muscarinic&#xD;
                  antagonist [LAMA], theophylline) are eligible.&#xD;
&#xD;
               -  Patients receiving fluticasone furoate/vilanterol with fluticasone furoate ≥ 200&#xD;
                  μg once daily are eligible.&#xD;
&#xD;
               -  Patients receiving budesonide/formoterol with budesonide ≥ 640 μg/day are&#xD;
                  eligible.&#xD;
&#xD;
               -  Patients requiring a third reliever/controller for their asthma are eligible.&#xD;
&#xD;
               -  Patients requiring maintenance oral corticosteroids (OCS) with a stable dose ≤ 10&#xD;
                  mg/day prednisone or equivalent OCS in addition to ICS are eligible; OCS total&#xD;
                  daily dose must have been stable at least 28 days prior to Screening.&#xD;
&#xD;
          3. Prebronchodilator (trough) forced expiratory volume in the first second of expiration&#xD;
             (FEV1) must be 40 to 85% of predicted normal at Screening and predose Baseline.&#xD;
&#xD;
          4. Patients must have ≥ 12% reversibility (and ≥ 200 mL difference) in FEV1 within 15 to&#xD;
             30 minutes after the administration of up to 4 puffs of albuterol/salbutamol at&#xD;
             Screening.&#xD;
&#xD;
          5. For patients not requiring maintenance OCS, blood eosinophil count ≥ 150 cells/μL at&#xD;
             Screening. An eosinophil count of ≥ 150 cells/μL in the medical record from the past&#xD;
             12 months may also be used to fulfil this criterion.&#xD;
&#xD;
          6. Asthma Control Questionnaire, 6-question (ACQ-6) score ≥ 1.5 at Screening and&#xD;
             Baseline.&#xD;
&#xD;
          7. Patient has experienced an asthma exacerbation at least once in the past 12 months,&#xD;
             defined here as:&#xD;
&#xD;
               -  Use of physician prescribed systemic corticosteroid [oral or parenteral], or&#xD;
&#xD;
               -  Asthma requiring treatment increase of approximately 4 times the baseline dose of&#xD;
                  ICS, or&#xD;
&#xD;
               -  Hospitalization or emergency medical care due to asthma.&#xD;
&#xD;
          8. Patient demonstrates acceptable inhaler, peak flow meter, and spirometry techniques&#xD;
             during the Screening Period in the opinion of the Investigator.&#xD;
&#xD;
          9. Patient demonstrates at least 70% compliance with usual asthma controller use during&#xD;
             Run-in Period, based on their patient diary.&#xD;
&#xD;
         10. Patient demonstrates at least 70% compliance with recording of symptom scores in the&#xD;
             patient-reported outcomes (PRO) diary completion during Run-in Period.&#xD;
&#xD;
         11. Patient is able to understand and willing to sign the informed consent form (ICF).&#xD;
&#xD;
         12. Patient is willing and able to comply with clinic visit schedule and study-related&#xD;
             procedures, in the opinion of the Investigator.&#xD;
&#xD;
         13. Non-sterilized male patients and their female partners of child-bearing potential&#xD;
             agree to practice adequate and effective forms of contraception through the duration&#xD;
             of the study from first dose to 8 weeks after the last dose of study drug.&#xD;
&#xD;
         14. Female patients of childbearing potential who are sexually active with a&#xD;
             non-sterilized male partner agree to practice adequate and effective forms of&#xD;
             contraception from first dose to 8 weeks after last dose of study drug.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
             -&#xD;
&#xD;
             A patient who meets any of the following criteria will be ineligible to participate in&#xD;
             this study:&#xD;
&#xD;
         15. Patient has a current diagnosis of a respiratory disorder other than asthma (eg,&#xD;
             active lung infection, chronic obstructive pulmonary disease (COPD), bronchiectasis,&#xD;
             pulmonary fibrosis, cystic fibrosis) or other disease associated with elevated&#xD;
             peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis,&#xD;
             Churg-Strauss syndrome, hypereosinophilic syndrome).&#xD;
&#xD;
         16. Patient has an acute upper or lower respiratory infection requiring antibiotics or&#xD;
             antiviral medication within 30 days prior to the date of informed consent or during&#xD;
             the Screening/Run-in Period. Note: Patients must be symptom-free for at least 30 days.&#xD;
&#xD;
         17. Patient experiences a severe asthma exacerbation at any time from 1 month prior to the&#xD;
             Screening Visit up to and including the Baseline Visit. Exacerbation is defined as:&#xD;
&#xD;
               -  Use of physician prescribed systemic corticosteroid [oral or parenteral], or&#xD;
&#xD;
               -  Asthma requiring treatment increase of approximately 4 times the baseline dose of&#xD;
                  ICS, or&#xD;
&#xD;
               -  Hospitalization or emergency medical care due to asthma.&#xD;
&#xD;
         18. Current smoker or former smoker with a smoking history of &gt; 10 pack-years. Note: This&#xD;
             includes tobacco, marijuana, and vaping products.&#xD;
&#xD;
         19. Patient is undergoing or planning to undergo any elective surgery during the study&#xD;
             requiring general anesthesia.&#xD;
&#xD;
         20. Patient has received treatment with any marketed (eg, omalizumab, benralizumab,&#xD;
             mepolizumab, reslizumab, dupilumab) or investigational biologic drug for asthma or&#xD;
             other diseases within 16 weeks or 5 half-lives prior to randomization, whichever is&#xD;
             longer.&#xD;
&#xD;
         21. Patient has received treatment with any investigational nonbiologic drug within 30&#xD;
             days or 5 half-lives prior to randomization, whichever is longer.&#xD;
&#xD;
         22. Patient did not respond favorably to previous dupilumab treatment (e.g. therapy&#xD;
             failure or patient experienced an adverse reaction to treatment).&#xD;
&#xD;
         23. Patient has received specific immunotherapy within 3 months prior to randomization.&#xD;
             Note: If the patient has received immunotherapy, a 3 month washout period is required&#xD;
             following the last dose of immunotherapy.&#xD;
&#xD;
         24. Patient is receiving medications or therapy that are prohibited as concomitant&#xD;
             medications.&#xD;
&#xD;
         25. Patient has a known or suspected history of immunosuppression, including history of&#xD;
             invasive opportunistic infections, such as aspergillosis, coccidioidomycosis,&#xD;
             histoplasmosis, HIV, listeriosis, pneumocystosis, pulmonary non-tuberculosis&#xD;
             mycobacteria, or tuberculosis, regardless of infection resolution; or unusually&#xD;
             frequent, recurrent, or prolonged infections. Note: Tuberculosis testing will be&#xD;
             performed on a country-by-country basis according to local guidelines if required by&#xD;
             regulatory authorities or ethics committees (ECs).&#xD;
&#xD;
         26. Patient has positive results at Screening for hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis B core antibody (HBcAb), or hepatitis C antibody (HCVAb) with positive HCV&#xD;
             RNA polymerase chain reaction; or positive HIV serology at Screening.&#xD;
&#xD;
         27. Patient has a helminth parasitic infection diagnosed within 24 weeks prior to the date&#xD;
             of informed consent that has not been treated with, or has failed to respond to,&#xD;
             standard of care therapy.&#xD;
&#xD;
         28. Patient shows evidence of acute or chronic infection requiring treatment with&#xD;
             antibacterials, antivirals, antifungals, antiparasitics, or antiprotozoals within 28&#xD;
             days of Screening, or significant viral infections within 28 days of Screening that&#xD;
             may not have received antiviral treatment (eg, influenza receiving only symptomatic&#xD;
             treatment).&#xD;
&#xD;
         29. Patient receives live (attenuated) vaccinations within 7 days of Screening or plans to&#xD;
             receive live (attenuated) vaccinations during the study.&#xD;
&#xD;
         30. Patient has any disorder that is not stable in the opinion of the Investigator and may&#xD;
             affect the safety of the patient throughout the study; influence the findings of the&#xD;
             studies or their interpretations; or impede the patient's ability to complete the&#xD;
             entire duration of study, including, but not limited to, cardiovascular,&#xD;
             gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious,&#xD;
             endocrine, metabolic, hematological, psychiatric, or major physical impairment.&#xD;
&#xD;
         31. Patient has any clinically significant abnormal findings in physical examination,&#xD;
             vital signs, or safety lab tests during Screening/Run-in Period; or any significant&#xD;
             medical history which, in the opinion of the Investigator, may put the patient at risk&#xD;
             because of his/her participation in the study, or may influence the results of the&#xD;
             study, or the patient's ability to complete entire duration of the study.&#xD;
&#xD;
         32. Patient is being treated with immunosuppressive therapy or biologic therapy for&#xD;
             autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary&#xD;
             biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis).&#xD;
&#xD;
         33. Patient has a prolonged corrected QT (QTc) interval (male &gt; 450 milliseconds, female &gt;&#xD;
             470 milliseconds) or tachyarrhythmia.&#xD;
&#xD;
         34. Patient has any of the following laboratory abnormalities at Screening:&#xD;
&#xD;
               -  Eosinophils &gt; 1500 cells/mmE3 or 1.5*10E9/L&#xD;
&#xD;
               -  Platelets &lt; 100000 cells/mmE3 or 100*10E9/L&#xD;
&#xD;
               -  Creatine phosphokinase (CPK) &gt; 10 times the upper limit of normal (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt; 2.5 times the ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) ≥ 2.5 times the ULN&#xD;
&#xD;
               -  Bilirubin &gt; 2 times the ULN.&#xD;
&#xD;
         35. Patient has a history of alcohol or drug abuse within 12 months of Screening.&#xD;
&#xD;
         36. Patient has an allergy to L-histidine, trehalose, or Tween (polysorbate) 80 or a&#xD;
             history of a systemic hypersensitivity reaction, other than localized injection site&#xD;
             reaction, to any biologic drug.&#xD;
&#xD;
         37. Patient has a history of malignancy within 5 years prior to the Baseline Visit, with&#xD;
             the following exceptions: patients with a history of completely treated carcinoma in&#xD;
             situ of cervix and nonmetastatic squamous or basal cell carcinoma of the skin are&#xD;
             allowed.&#xD;
&#xD;
         38. Female patient is pregnant, planning to become pregnant, or is breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzhou Connect</last_name>
    <role>Study Director</role>
    <affiliation>Suzhou Connect Biopharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malinda Longphre, PhD</last_name>
    <phone>+15105203361</phone>
    <email>mlongphre@connectpharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maryam Yaghini</last_name>
    <phone>+14156106887</phone>
    <email>myaghini@connectpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Connect Investigative Site 109</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 125</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 103</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 114</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 104</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 118</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 105</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 124</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 120</name>
      <address>
        <city>White Marsh</city>
        <state>Maryland</state>
        <zip>21162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 112</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 119</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 111</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 117</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 107</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 113</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 101</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 116</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 102</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 121</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 108</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 106</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 115</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>May 16, 2021</last_update_submitted>
  <last_update_submitted_qc>May 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

